Nanovibronix Inc represents core values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on improving patients' lives through cutting-edge medical devices and solutions, Nanovibronix Inc sets itself apart in the healthcare industry. The company thrives on continuous research and development, delivering advanced technologies that address unmet clinical needs. Nanovibronix Inc's commitment to improving patient outcomes and its dedication to providing healthcare professionals with effective tools make it a trusted partner. With a passion for creating impactful solutions, Nanovibronix Inc consistently demonstrates its commitment to enhancing the quality of life for patients globally.

Nanovibronix Inc is primarily present in the United States and Israel.

Nanovibronix Inc has achieved significant milestones in its journey. The company has successfully developed and commercialized innovative medical devices, focused on pain management and wound healing. It has received FDA clearance and approvals for several of its groundbreaking products, including PainShield® and WoundShield™. Nanovibronix Inc has also established strategic partnerships and collaborations, further enhancing its market presence and global reach. The company's commitment to research and development has led to advancements in therapeutic ultrasound technology, improving patient outcomes and quality of life. Nanovibronix Inc continues to revolutionize the medical industry with its cutting-edge solutions and remains poised for future growth and success.

Nanovibronix Inc, a reputable company in the stock market, boasts a rich history and background. With a drive for innovation and technological advancements, Nanovibronix Inc specializes in the development of medical devices using low-intensity surface acoustic wave technology. Founded in [insert year], the company has continuously aimed to revolutionize the healthcare industry by providing non-invasive and cost-effective solutions for various medical conditions. Nanovibronix Inc has garnered recognition for its cutting-edge products, including PainShield® and WoundShield™, which have shown exceptional efficacy in pain management and wound healing. With a steadfast commitment to improving patient outcomes, Nanovibronix Inc remains at the forefront of medical device innovation.

The main competitors of Nanovibronix Inc in the market include companies such as Johnson & Johnson, Medtronic, Philips, and Siemens Healthineers.

Nanovibronix Inc primarily operates in the medical and healthcare industry.

Nanovibronix Inc operates under a business model that centers around the development and commercialization of innovative medical devices. The company specializes in utilizing proprietary low-intensity ultrasound technology for various therapeutic applications. Nanovibronix Inc's products aim to provide non-invasive and drug-free solutions for pain relief, wound healing, and infection control. By leveraging ultrasound technology, the company aims to offer cost-effective and convenient alternatives to traditional treatment methods. Nanovibronix Inc is committed to advancing healthcare through its cutting-edge devices, contributing to improved patient outcomes and overall well-being.

De K/W-verhouding kan momenteel niet worden berekend voor Nanovibronix.

De KUV kan momenteel niet worden berekend voor Nanovibronix.

De AlleAktien Kwaliteitsscore voor Nanovibronix is 6/10.

De omzet kan momenteel niet worden berekend voor Nanovibronix.

De winst kan momenteel niet berekend worden voor Nanovibronix.

Nanovibronix Inc is a US-based company specializing in the development and manufacturing of medical devices and retail products. The company aims to develop and distribute innovative solutions for medical problems to help patients.

Nanovibronix keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Nanovibronix of het bedrijf keert geen dividend uit.

De ISIN van Nanovibronix is US63008J1088.

Het WKN van Nanovibronix is A2QB7C.

De ticker van Nanovibronix is NAOV.

Binnen de laatste 12 maanden betaalde Nanovibronix een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Nanovibronix naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Nanovibronix is momenteel .

Nanovibronix betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Nanovibronix betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Nanovibronix wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Nanovibronix van 25-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 25-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 25-7-2024.

In het jaar 2023 heeft Nanovibronix 0 USD aan dividenden uitgekeerd.

De dividenden van Nanovibronix worden in USD uitgekeerd.